Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide.

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Despite the jump in the number of teens being prescribed Wegovy, it still represents only a small fraction of kids who are living with obesity. Approximately one in 5 children and teens in the U.S.

In 2023, the rate of first-time Wegovy prescriptions was 9.9 per 100,000 adolescents. That figure rose to 14.8 per 100,000 in 2024 — a 50% increase. First-time Saxenda prescriptions remained ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

EMA’s safety committee concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus & Wegovy: Amsterdam, The Netherlands Monday, June 9, 2 ...

Almonds, pistachios, and walnuts may help boost GLP-1 thanks to their fiber, protein, and healthy fats. These nutrients work ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...